^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DLL3 inhibitor

    Related drugs:
    1d
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Mar 2026 --> Jun 2026
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    4d
    DeLLphi-309: A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (clinicaltrials.gov)
    P2, N=252, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Imdelltra (tarlatamab-dlle)
    9d
    Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database. (PubMed, Clin Lung Cancer)
    Concurrent radiotherapy with tarlatamab is safe, with low severe toxicity, frequent local tumor response, and a trend toward improved OS, supporting further study in ES-SCLC.
    Journal • Pan tumor
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Imdelltra (tarlatamab-dlle)
    9d
    Early Experience with Tarlatamab (T-Cell Engagers) for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Canada: Lessons Learned and Implementation Strategies. (PubMed, Curr Oncol)
    By sharing insights into administration protocols, dose ramp-up procedures, post-cycle 1 monitoring, and AE management strategies implemented at their centres, early adopters of tarlatamab can help other institutions develop and refine their own protocols more efficiently. Lessons learned during the early implementation phase, including the roles of various healthcare providers and the transition from inpatient to outpatient care, should facilitate the smoother integration of tarlatamab and other TCEs for solid tumours into clinical pathways across Canada.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Imdelltra (tarlatamab-dlle)
    17d
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC (clinicaltrials.gov)
    P1, N=138, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    17d
    DAREONTM-9: DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Jul 2027
    Enrollment closed • Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    topotecan • obrixtamig (BI 764532)
    17d
    CSET 2024/4014: Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), with biomarker analysis to characterize response/resistance (UNLOCK TARLATAMAB) (2024-515847-47-00)
    P1/2, N=40, Recruiting, Institut Gustave Roussy
    New P1/2 trial
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • DLL3 (Delta Like Canonical Notch Ligand 3) • NCAM1 (Neural cell adhesion molecule 1)
    |
    DLL3 expression • DLL3 positive
    |
    Imdelltra (tarlatamab-dlle)
    18d
    A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    18d
    GCO-003 TARLANEC: Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs) (2024-515948-23-00)
    P2/3, N=129, Recruiting, Intergroupe Francophone De Cancerologie Thoracique
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • docetaxel • 5-fluorouracil • temozolomide • irinotecan • dacarbazine • topotecan • Imdelltra (tarlatamab-dlle)
    18d
    20240178: Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312) (2024-520050-38-00)
    P2/3, N=129, Recruiting, Amgen Inc.
    New P2/3 trial
    |
    carboplatin • Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle) • Sylvant (siltuximab)
    18d
    RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab (2024-514327-42-00)
    P1/2, N=87, Recruiting, Grupo Espanol De Tumores Neuroendocrinos
    New P1/2 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    5-fluorouracil • Imdelltra (tarlatamab-dlle)
    18d
    20240124: Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-310) (2024-515903-21-00)
    P1, N=47, Recruiting, Amgen Inc.
    New P1 trial
    |
    Imdelltra (tarlatamab-dlle)